|
- 2019
Randomized, double‐blind, placebo‐controlled study of interferon‐γ 1b in Friedreich AtaxiaDOI: 10.1002/acn3.731 Abstract: In vitro, in vivo, and open‐label studies suggest that interferon gamma (IFN‐γ 1b) may improve clinical features in Friedreich Ataxia through an increase in frataxin levels. The present study evaluates the efficacy and safety of IFN‐γ 1b in the treatment of Friedreich Ataxia through a double‐blind, multicenter, placebo‐controlled trial
|